{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:04:34Z","timestamp":1792706674069,"version":"4.5.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"Supplement_3","license":[{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Several studies have shown hydrocortisone to be beneficial in the treatment of vasopressor-refractory septic shock, but there are minimal data evaluating the efficacy of this fixed dosing regimen in overweight and obese patients. The purpose of this study was to compare the effects of fixed-dose hydrocortisone on vasopressor dose and mean arterial pressure in obese and nonobese patients with septic shock refractory to adequate fluid resuscitation and vasopressor administration.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this multicenter, retrospective study, we included adult patients with a confirmed or suspected diagnosis of septic shock who received hydrocortisone (200 mg\/day). Patients were divided into 4 study groups based on admission body mass index (BMI; defined as BMI of &amp;lt;25 kg\/m2, 25-29.9 kg\/m2, 30-34.9 kg\/m2, and \u226535 kg\/m2). The primary outcomes analyzed were change in norepinephrine equivalent dose requirements and mean arterial pressure (MAP) at 6, 12, and 24 hours after initiating hydrocortisone.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Between October 1, 2017, and September 30, 2020, 431 patients were screened of whom 219 met inclusion criteria. Baseline characteristics were comparable among the groups. Mean vasopressor requirements (in \u03bcg\/min) at 6, 12, and 24 hours were as follows: BMI of &amp;lt;25 kg\/m2: 28.8, 24.8, and 20; BMI of 25-29.9 kg\/m2: 34.1, 33.5, and 24.8; BMI of 30-34.9 kg\/m2: 29.5, 33.5, and 24.8; and BMI of \u226535 kg\/m2: 32, 25.7 and, 21.2 (P = 0.75, 0.41, and 0.61, respectively). Mean MAP (in mm Hg) at 6, 12, and 24 hours was as follows: BMI of &amp;lt;25 kg\/m2: 73.5, 73.6, and 74; BMI of 25-29.9 kg\/m2: 71.6, 73.8, and 71.9; BMI of 30-34.9 kg\/m2: 72.2, 70, and 72.7; and BMI of \u226535 kg\/m2: 70.7, 73.5, and 71.4 (P = 0.56, 0.15, and 0.62, respectively).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>BMI does not appear to impact the effects of fixed-dose hydrocortisone on vasopressor dose or blood pressure in patients with septic shock. Fixed-dose hydrocortisone should continue to be used for vasopressor-refractory septic shock in obese patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxac156","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T11:20:18Z","timestamp":1654600818000},"page":"S94-S99","source":"Crossref","is-referenced-by-count":4,"title":["Effect of fixed-dose hydrocortisone on vasopressor dose and mean arterial pressure in obese and nonobese patients with septic shock"],"prefix":"10.1093","volume":"79","author":[{"given":"Morgan","family":"Lenney","sequence":"first","affiliation":[{"name":"Banner University Medical Center\u2013Tucson , Tucson, AZ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Kopp","sequence":"additional","affiliation":[{"name":"Banner University Medical Center\u2013Tucson , Tucson, AZ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Erstad","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Science, University of Arizona College of Pharmacy , Tucson, AZ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,6,7]]},"reference":[{"issue":"11","key":"2022081908573872300_CIT0001","doi-asserted-by":"crossref","first-page":"e1063","DOI":"10.1097\/CCM.0000000000005337","article-title":"Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021","volume":"49","author":"Evans","year":"2021","journal-title":"Crit Care Med"},{"key":"2022081908573872300_CIT0002","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.3389\/fimmu.2020.01318","article-title":"Glucocorticoids in sepsis: to be or not to be","volume":"11","author":"Vandewalle","year":"2020","journal-title":"Front Immunol"},{"issue":"7","key":"2022081908573872300_CIT0003","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/jama.288.7.862","article-title":"Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock","volume":"288","author":"Annane","year":"2002","journal-title":"JAMA"},{"issue":"2","key":"2022081908573872300_CIT0004","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa071366","article-title":"Hydrocortisone therapy for patients with septic shock","volume":"358","author":"Sprung","year":"2008","journal-title":"N Engl J Med"},{"issue":"9","key":"2022081908573872300_CIT0005","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1705716","article-title":"Hydrocortisone plus fludrocortisone for adults with septic shock","volume":"378","author":"Annane","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"2022081908573872300_CIT0006","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa1705835","article-title":"Adjunctive glucocorticoid therapy in patients with septic shock","volume":"378","author":"Venkatesh","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"2022081908573872300_CIT0007","first-page":"963","article-title":"Pharmacokinetics and pharmacodynamics of prednisolone in obese rats","volume":"250","author":"Nichols","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"2022081908573872300_CIT0008","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jaip.2015.11.013","article-title":"Corticosteroid pharmacokinetic abnormalities in overweight and obese corticosteroid resistant asthmatics","volume":"4","author":"Goleva","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"2022081908573872300_CIT0009","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1164\/rccm.200801-076OC","article-title":"Body mass and glucocorticoid response in asthma","volume":"178","author":"Sutherland","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"2022081908573872300_CIT0010","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1210\/jcem.86.9.7826","article-title":"Resistance to glucocorticoid feedback in obesity","volume":"86","author":"Jessop","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"16","key":"2022081908573872300_CIT0011","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1214969","article-title":"Reduced cortisol metabolism during critical illness","volume":"368","author":"Boonen","year":"2013","journal-title":"N Engl J Med"},{"issue":"8","key":"2022081908573872300_CIT0012","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"2022081908573872300_CIT0013","author":"Centers"},{"issue":"9","key":"2022081908573872300_CIT0014","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa067373","article-title":"Vasopressin versus norepinephrine infusion in patients with septic shock","volume":"358","author":"Russell","year":"2008","journal-title":"N Engl J Med"},{"issue":"5","key":"2022081908573872300_CIT0015","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jpainsymman.2016.12.333","article-title":"Intensity of vasopressor therapy for septic shock and the risk of in-hospital death","volume":"53","author":"Brand","year":"2017","journal-title":"J Pain Symptom Manage"},{"issue":"4","key":"2022081908573872300_CIT0016","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/SHK.0000000000001086","article-title":"Body mass\u2019s impact on response to fixed-dose vasopressin in patients with septic shock","volume":"50","author":"Torbic","year":"2018","journal-title":"Shock"},{"issue":"9","key":"2022081908573872300_CIT0017","first-page":"501","article-title":"Effect of fat distribution on the pharmacokinetics of cortisol in obesity","volume":"36","author":"Lottenberg","year":"1998","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"7","key":"2022081908573872300_CIT0018","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1210\/js.2017-00215","article-title":"Alterations in hydrocortisone pharmacokinetics in a patient with congenital adrenal hyperplasia following bariatric surgery","volume":"1","author":"Mallappa","year":"2017","journal-title":"J Endocr Soc"},{"issue":"5","key":"2022081908573872300_CIT0019","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/clpt.1991.64","article-title":"Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity","volume":"49","author":"Dunn","year":"1991","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"2022081908573872300_CIT0020","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/clpt.1984.263","article-title":"Prednisolone disposition in obese men","volume":"36","author":"Milsap","year":"1984","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"2022081908573872300_CIT0021","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/MED.0000000000000066","article-title":"Cortisol metabolism in critical illness: implications for clinical care","volume":"21","author":"Boonen","year":"2014","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"5","key":"2022081908573872300_CIT0022","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/SHK.0000000000000665","article-title":"Effects of increasing hydrocortisone to 300 mg per day in the treatment of septic shock: a pilot study","volume":"46","author":"Hyvernat","year":"2016","journal-title":"Shock"},{"key":"2022081908573872300_CIT0023","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jcrc.2020.12.001","article-title":"Comparison of shock reversal with high or low dose hydrocortisone in intensive care unit patients with septic shock: a retrospective cohort study","volume":"62","author":"Bonnin","year":"2021","journal-title":"J Crit Care"},{"issue":"12","key":"2022081908573872300_CIT0024","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1097\/CCM.0000000000002737","article-title":"Guidelines for the Diagnosis and Management of Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in Critically Ill Patients (Part 1): Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM): 2017","volume":"45","author":"Annane","year":"2017","journal-title":"Crit Care Med"},{"issue":"10","key":"2022081908573872300_CIT0025","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s00134-014-3635-7","article-title":"Ten false beliefs about cortisol in critically ill patients","volume":"41","author":"Venkatesh","year":"2015","journal-title":"Intensive Care Med"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxac156\/44225920\/zxac156.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/79\/Supplement_3\/S94\/45472934\/zxac156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/79\/Supplement_3\/S94\/45472934\/zxac156.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T08:58:14Z","timestamp":1660899494000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/79\/Supplement_3\/S94\/6603617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,7]]},"references-count":25,"journal-issue":{"issue":"Supplement_3","published-online":{"date-parts":[[2022,6,7]]},"published-print":{"date-parts":[[2022,8,19]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxac156","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,9,1]]},"published":{"date-parts":[[2022,6,7]]}}}